TABLE 9.
Multivariate analysis of OS for EPSILoN
| Covariate | Category | Multivariate analysis | |
|---|---|---|---|
| HR (95% CI) | p value | ||
| Clinical stage | IV | 1.284 (0.728–2.262) | 0.388 |
| ECOG PS | 2–3 | 4.909 (2.838–8.493) | <0.001* |
| Number of metastatic sites | ≥3 | 1.444(0.872–2.391) | 0.153 |
| Line of immunotherapy | ≥3 | 1.485 (1.049–2.102) | 0.026* |
| Liver metastases | Yes | 1.355 (0.842–2.180) | 0.210 |
| Brain metastases | Yes | 1.238(0.822–1.862) | 0.307 |
| Bone metastases | Yes | 1.097 (0.727–1.655) | 0.659 |
| NLR | ≥4 | 2.091 (1.457–3.001) | <0.001* |
| LDH | >1.5*ULN | 3.020(1.939–4.703) | <0.001* |
Abbreviations: dNLR, derived neutrophil‐to‐lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; NLR, neutrophil‐to‐lymphocyte ratio; OS, overall survival; PLR, platelet‐to‐lymphocyte ratio.
*
p < 0.05.